Today, Ryan runs an ever - expanding group of engineers tasked
with building out
new products at pace while stressing a culture of agility and
experimentation, even as Credit Karma reaches
new levels of scale.
To
build upon the encouraging early discoveries, Helmsley renewed and expanded its Crohn's funding for the Institute in 2013 to begin
new work
with three major aims: 1) continue studies of individual genes to determine how genetic differences between Crohn's patients and healthy individuals contribute to the disease; 2) evaluate promising small molecules in disease - relevant studies and prioritize insights from genetics to help develop novel therapeutics; and 3) begin basic
experimentation in animal models
with Crohn's disease to provide the data necessary to begin testing
new therapies in humans.